PCSK9 and Hypertension: In two secondary analyses, after stratification of FH patients according to smoking and hypertension respectively, we observed a significant reduction of serum CLC in smokers and hypertensive patients after 6 months of PCSK9-i treatment (Supplementary Tables S1, S2, Supplementary Material).